



**The Clatterbridge  
Cancer Centre**  
NHS Foundation Trust

Clatterbridge Road  
Bebington  
Wirral  
CH63 4JY

Tel: 0151 556 5000  
Web: [www.clatterbridgecc.nhs.uk](http://www.clatterbridgecc.nhs.uk)

Date: 10<sup>th</sup> May 2018

**Re: Freedom of Information Request**  
**Ref: 76- 2018**

Thank you for your email dated 16th April 2018 requesting information regarding urothelial cell cancer.

The information that you require is as follows:

**Please find response attached below**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**

## FOI Request re Urothelial Cancer Patients

Please indicate the number of metastatic or locally advanced Urothelial<sup>1</sup> cancer patients treated<sup>2</sup> by your Trust in the 3 months, December 2017 to February 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated	25	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive, please indicate the number treated with the following therapies.

Therapy	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Cisplatin (mono or combination therapy)	8	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)	1	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	11	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	0	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

---



---

<sup>1</sup> ICD10 C65, C66, C67, C68; TNM staging for metastatic Urothelial Cancer = Any T, any N, M1; TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0; Please include numbers for:

- any diagnosis of metastatic disease as opposed to patients that present with metastases
- all metastatic sites from a Urothelial primary

<sup>2</sup> Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.